Marissa N. Balak

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Medicine, Genetics, Oncology +17

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Marissa N. Balak, Yixuan Gong, Gregory J. Riely et al. · Clinical Cancer Research · 2006 · 829 citations

Medicine, Oncology, Pharmacology +14

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Hyo-Eun Carrie Bhang, David A. Ruddy, Viveksagar Krishnamurthy Radhakrishna et al. · Nature Medicine · 2015 · 527 citations

Life Sciences, Bioinformatics, Oncology +16

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

Yixuan Gong, Romel Somwar, Katerina Politi et al. · PLoS Medicine · 2007 · 315 citations · Full text

Medicine, Oncology, Pharmacology +17

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

James Bean, Gregory J. Riely, Marissa N. Balak et al. · Clinical Cancer Research · 2008 · 276 citations · Full text

Medicine, Oncology, Pharmacology +14